Beruflich Dokumente
Kultur Dokumente
VO L . 4 0 , N O. 2 3
Internal Medicine News www.eclinicalpsychia
www.inter nalmedicinenews.com
tr ynews.com
T he Leading Inde p endent Ne wspaper for the Inter nist—Since 1968 DECEMBER 1, 2007
INSIDE
Fenofibrate Curbed
Retinopathy in
S HERI M ATTES /E LSEVIER G LOBAL M EDICAL N EWS
Diabetic Patients
Need for laser therapy was cut by 37%.
Early Signs of BY MITCHEL L. ZOLER with [diabetic retinopathy] is very
Parkinson’s Philadelphia Bureau exciting. It’s exciting to use it to
Preclinical brain changes can treat patients, and it opens a
be seen on SPECT images. O R L A N D O — Treatment with whole new area of research,”
fenofibrate led to a substantial commented Dr. Virgil Brown,
PAGE 13 drop in the need for laser treat- professor of internal medicine at
Improved reimbursement is “a very urgent issue,” said Dr. David ments for retinopathy in a con- Emory University, Atlanta.
C. Dale, president of the American College of Physicians. trolled trial of nearly 10,000 pa- The benefits of fenofibrate for
tients with type 2 diabetes. microvascular disease of diabetes
Family History Physicians should “consider us- appeared to extend beyond its sig-
with prehypertension,
Several professional societies—includ-
ing the American Society of Colon and
Rectal Surgeons—have added such warn-
naturally. ings to their consensus documents on
bowel preparation.
This increased awareness will likely lead
to a decline in acute phosphate nephropa-
thy, Dr. Markowitz said. Clinicians will be
more careful in selecting purgatives for
each patient. Several manufacturers of
bowel preparations have decreased their
phosphate content by 16%-20%. Also, clin-
icians are increasingly recommending bet-
ter hydration, to provide at least 72 ounces
before, during, and after the use of oral
sodium phosphate purgatives. ■
EDITORIAL
A DV I S O RY B OA R D
ROY D. ALTMAN, M.D., California
Introducing ameal bp™ – the new dietary supplement containing the naturally derived active ingredient
JON O. EBBERT, M.D., Minnesota
AmealPeptide®, clinically shown to maintain healthier blood pressure in prehypertensive patients.*
FAITH T. FITZGERALD, M.D., California
AmealPeptide® is a naturally occurring ACE inhibitor derived from enzymatically hydrolized WILLIAM E. GOLDEN, M.D., Arkansas
casein (milk proteins). Fourteen double-blind, placebo-controlled studies have shown a SIDNEY GOLDSTEIN, M.D., Michigan
clinically significant lowering of both systolic and diastolic blood pressure ROBERT H. HOPKINS, M.D., Arkansas
Stratified analysis of 8 clinical studies by start value of blood pressure
(Post-hoc analysis, 606 subjects from 8 studies) with AmealPeptide®. It has also been shown to be safe and well-tolerated.
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
HOLLY J. KRAMER, M.D., Illinois
10
~160 159~150 149~140 139~130 ~100 99~95 94~90 89~85 ameal bp™ is available online or at major drugstores in easy-to-swallow J. LEONARD LICHTENFELD, M.D., Georgia
0 capsules and chewable tablets. DIANE E. MEIER, M.D., New York
-10
**
**
Start prehypertensive patients on ameal bpTM when you F. MICHAEL MELEWICZ, M.D., California
*** **
-20
*** ***
***
AmealPeptide ®
start them on a diet and exercise program. ALAN R. NELSON, M.D., Washington, D.C.
-30 Placebo
JOHN R. NELSON, M.D., Washington
Significant difference from placebo (t-test): **P<0.01, ***P<0.001.
Visit www.amealbp.com for more information.
BARBARA L. SCHUSTER, M.D., Ohio
Reference: 1. Data on file. Post-hoc analysis adapted from
AmealPeptide® clinical studies. DONNA E. SWEET, M.D., Kansas
ERIC G. TANGALOS, M.D., Minnesota
PETER G. TUTEUR, M.D., Missouri
JOHN H. VASSALL II, M.D., Washington
*This statement has not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease. JOHN J. WHYTE, M.D., Washington, D.C.
ameal bp™ and AmealPeptide® are trademarks of Calpis Co., Ltd. Helps maintain healthy blood pressure* ROWEN K. ZETTERMAN, M.D., Nebraska
©2007 Calpis Co., Ltd. A02
Technical Consultant:
GILMAN D. GRAVE, M.D.